Prime Medicine and Beam Therapeutics had common origins in gene editing. Now they're both pursuing treatments for the same ...

Beam Therapeutics reported promising Phase 1/2 data for BEAM-302, demonstrating durable gene correction for AATD. See why I ...

We recently published a list of 10 Best Growth Stocks to Invest in for the Next 10 Years. In this article, we are going to ...

Beam Therapeutics (NASDAQ:BEAM – Get Free Report)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright ...

The Cambridge-based company touted the data as evidence of the first successful use of CRISPR gene editing to fix a ...

Wedbush reaffirmed their outperform rating on shares of Beam Therapeutics (NASDAQ:BEAM – Free Report) in a research note ...

Fintel reports that on March 10, 2025, Jones Trading upgraded their outlook for Beam Therapeutics (NasdaqGS:BEAM) from Hold ...

Beam Therapeutics (BEAM) announced initial safety and efficacy data from its Phase 1/2 trial of BEAM-302, establishing clinical ...

Cargo was founded by two highly acclaimed cell-therapy researchers. The company raised over $500 million to develop ...

Beam Therapeutics shares were 14% lower, at $24.60, after the company priced an underwritten offering with proceeds of $500 million. The biotechnology company said it is offering 16.2 million shares ...

CAMBRIDGE, Mass., March 10, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the ...

Cathie Wood-led Ark Invest made notable trades, buying IRDM, BEAM, PACB, ABSI and selling ILMN, RPTX, AMGN, VEEV.